Designer Anabolic Steroid Control Act of 2014

Designer Anabolic Steroid Control Act of 2014

Long title	To amend the Controlled Substances Act to more effectively regulate anabolic steroids.
Announced in	the 113th United States Congress
Sponsored by	Rep. Joseph R. Pitts (R, PA-16)
Number of co-sponsors	1
Codification
U.S.C. sections affected	21 U.S.C. § 355, 18 U.S.C. § {{{2}}}, 21 U.S.C. § 825, 21 U.S.C. § 811, 21 U.S.C. § 802, and others.
Agencies affected	United States Department of Justice, Drug Enforcement Administration, Department of Health and Human Services
Legislative history
Introduced in the House as H.R. 4771 by Rep. Joseph R. Pitts (R, PA-16) on May 29, 2014 Committee consideration by House Committee on Energy and Commerce, House Committee on the Judiciary, United States House Judiciary Subcommittee on Crime, Terrorism, Homeland Security and Investigations Passed the House on September 15, 2014 (voice vote) Passed the Senate on December 11, 2014 (voice vote) Signed into law by President Barack Obama on December 18, 2014

The Designer Anabolic Steroid Control Act of 2014 (H.R. 4771) is a bill that expanded the list of anabolic steroids regulated by the Drug Enforcement Administration (DEA) to include about two dozen new substances and established new crimes relating to false labeling of steroids.^[1] The bill established a penalty of up to $500,000 against those found to be falsely labeling their anabolic steroid products.^[2]

Specifically, the text of the bill reads: "In the case of a violation...by an importer, exporter, manufacturer, or distributor...up to $500,000 per violation...For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute.

The bill further reads: "In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of...this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term at the retail level refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation...shall be considered a separate violation. "

The bill was introduced into the United States House of Representatives during the 113th United States Congress. Barack Obama signed the bill into law on December 18, 2014.